How CAR-NK Cells Could Work Better than CAR-T Cells
James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
”The major hurdle addressed is donor cell rejection by the recipient’s immune system, which the authors determined is primarily mediated by host CD8+ T cells.
To overcome rejection, the researchers engineered a single gene construct that combines a selective shRNA to knock down rejection-related HLA Class I molecules, a Chimeric Antigen Receptor (CAR) for tumor targeting, and the expression of immune checkpoint ligands like PD-L1 or single-chain HLA-E (SCE).
This integrated approach not only enabled the CAR-NK cells to evade host-mediated rejection in mouse models but also surprisingly enhanced their anti-tumor activity and provided a favorable safety profile by reducing inflammatory cytokines.”
Stay updated with Hemostasis Today.
-
Aug 22, 2026, 13:38Jerome Hadjadj: A New Approach to Refractory Immune Thrombocytopenia
-
Aug 22, 2026, 13:25Christopher Robinson: Hematologic Response to Iron Therapy and Stillbirth Risk
-
Aug 22, 2026, 13:24Philippa Hill: Blood Clot Awareness – Recognize the Signs, Prevent the Risk
-
Aug 22, 2026, 13:21Chokri Ben Lamine: ASH 2026 Adult Primary ITP Guidelines – Practice-Changing Update
-
Aug 22, 2026, 13:07Saneha Anjum Shaikh: Blood Bank Basics and Quality Control in Automation
-
Aug 22, 2026, 11:36Bernardo Gindri: How platelets Influence Cancer Progression
-
Aug 22, 2026, 11:34Nick Gehrig: Extending Platelet Shelf Life to Strengthen Blood Supply
-
Aug 22, 2026, 11:14Lei Yu: New Guidance for Acute Pulmonary Embolism in 2026
-
Aug 22, 2026, 11:01Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?